All In Biotech

Drug Trial Radar · NCT05829226

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

101

Actual

Start

Dec 12, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
PureTechIndustry
Sponsor type
Industry
First posted
Apr 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)

Conditions

  • AML, Adult Recurrent
  • MDS

Interventions

  • LYT-200Drug

    monoclonal antibody (mAb), targeting galectin-9 protein

  • VenetoclaxDrug

    Bcl-2 inhibitor

  • AzacitidineDrug

    Hypomethylating agent

  • DecitabineDrug

    Hypomethylating agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination]Time frame: approximately 1 year
  2. Incidence of Dose Limiting Toxicities [Tolerability and RP2D determination]Time frame: approximately 1 year

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Irvine Medical Center

    Orange, California

  • Baptist Health South Florida-Miami Cancer Institute

    Miami, Florida

  • Norton Healthcare-Norton Cancer Institute

    Louisville, Kentucky

  • Mass. General Hospital-Harvard

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Rhode Island Hospital

    Providence, Rhode Island

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.